Join experts Drs Kevin Kalinsky and Aditya Bardia as they discuss utilizing antibody-drug conjugates in clinic. What is currently available? What are the possible side effects? Tune in to find out.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991254). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

Introduction to Antibody-drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/

Antibody-drug Conjugates Targeting TROP-2: Clinical Development in Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36302269/

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

HER2 Status in Breast Cancer: Changes in Guidelines and Complicating Factors for Interpretation https://pubmed.ncbi.nlm.nih.gov/31693827/

Whole-exome Sequencing Identifies Somatic Mutations and Intratumor Heterogeneity in Inflammatory Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34075047/

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/

Trastuzumab Deruxtecan in Previously Treated HER2-low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/

TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2-metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32223649/

Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/

Scalp Cooling to Prevent Chemotherapy-induced Alopecia https://pubmed.ncbi.nlm.nih.gov/32622629/

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) https://www.clinicaltrials.gov/search?term=NCT03401385

Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-low Breast Cancer https://ascopost.com/issues/january-25-2023/neoadjuvant-t-dxd-demonstrates-activity-in-phase-ii-study-of-patients-with-her2-low-breast-cancer/

Sacituzumab Govitecan in TNBC (NeoSTAR) https://clinicaltrials.gov/study/NCT04230109

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) https://www.clinicaltrials.gov/study/NCT05629585

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) https://www.clinicaltrials.gov/study/NCT05633654